Loading...
SDZ logo

Sandoz Group AGSWX:SDZ Voorraadrapport

Marktkapitalisatie CHF 27.1b
Prijs aandeel
CHF 62.54
CHF 66.01
5.3% ondergewaardeerd intrinsieke korting
1Y70.4%
7D-1.2%
Portefeuillewaarde
​
Bekijk

Sandoz Group AG

SWX:SDZ Voorraadrapport

Marktkapitalisatie: CHF 27.1b

Sandoz Group (SDZ) Aandelenoverzicht

Sandoz Group AG ontwikkelt, produceert en verkoopt wereldwijd generieke geneesmiddelen en biosimilars. Meer informatie

Beloningen

Verhandeld tegen 39.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 16.75% per jaar groeien

Risicoanalyse

Geen risico's gedetecteerd voor SDZ uit onze risicocontroles.

SDZ Community Fair Values

Create Narrative

See what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 64.4% ondergewaardeerd intrinsieke korting
5419.8%Revenue growth p.a.
6.2k
18
0
128
3mo ago

Sandoz Group AG Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Sandoz Group
Historische aandelenkoersen
Huidige aandelenkoersCHF 62.54
52 Week HoogtepuntCHF 72.70
52 Week LaagCHF 36.22
Bèta0.61
1 maand verandering-2.28%
3 maanden verandering2.09%
1 Jaar Verandering70.36%
3 jaar veranderingn/a
5 jaar veranderingn/a
Verandering sinds IPO156.84%

Recent nieuws en updates

SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E

The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.

SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans

Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.

Recent updates

SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E

The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.

SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans

Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.

SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E

Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.

SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E

Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.

SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence

Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.

SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks

Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.

SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks

Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.

SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks

Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.

SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion

Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.

SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance

Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.

SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead

The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.

SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance

The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.

Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)

Rendement voor aandeelhouders

SDZCH PharmaceuticalsCH Markt
7D-1.2%0.3%-0.3%
1Y70.4%24.3%7.0%

Rendement versus industrie: SDZ overtrof de Swiss Pharmaceuticals industrie, die het afgelopen jaar een rendement 24.3 % opleverde.

Rendement versus markt: SDZ overtrof de Swiss markt, die het afgelopen jaar een rendement opleverde van 7 %.

Prijsvolatiliteit

Is SDZ's price volatile compared to industry and market?
SDZ volatility
SDZ Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement4.5%
10% most volatile stocks in CH Market8.3%
10% least volatile stocks in CH Market2.2%

Stabiele aandelenkoers: SDZ heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swiss markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van SDZ is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
188622,356Richard Saynorwww.sandoz.com

Sandoz Group AG ontwikkelt, produceert en verkoopt wereldwijd generieke geneesmiddelen en biosimilars. Het bedrijf richt zich op therapeutische gebieden, waaronder hart- en vaatziekten, het centrale zenuwstelsel, oncologie, infectieziekten, pijn en luchtwegen, diabetes, immunologie, endocrinologie, hematologie en oogheelkunde. Het biedt ook een portfolio van actieve farmaceutische ingrediënten en afgewerkte doseringsvormen.

Sandoz Group AG Samenvatting

Hoe verhouden de winst en inkomsten van Sandoz Group zich tot de beurswaarde?
SDZ fundamentele statistieken
MarktkapitalisatieCHF 27.06b
Inkomsten(TTM)CHF 714.46m
Inkomsten(TTM)CHF 8.72b
37.9x
Koers/Winstverhouding
3.1x
P/S-verhouding

Is SDZ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SDZ resultatenrekening (TTM)
InkomstenUS$11.16b
Kosten van inkomstenUS$5.86b
BrutowinstUS$5.30b
Overige uitgavenUS$4.39b
InkomstenUS$914.00m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

Aug 05, 2026

Winst per aandeel (EPS)2.11
Brutomarge47.50%
Nettowinstmarge8.19%
Schuld/Eigen Vermogen Verhouding56.6%

Hoe presteerde SDZ op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.3%
Huidig dividendrendement
48%
Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/03 07:56
Aandelenkoers aan het einde van de dag2026/04/30 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Sandoz Group AG wordt gevolgd door 37 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Emily FieldBarclays
James GordonBarclays
Sidhartha ModiBarclays